Investigational 2.0 mg dose of Ozempic® (semaglutide) demonstrates superior reductions in blood sugar vs Ozempic® 1.0 mg in adults with type 2 diabetes in a phase 3 trial

Pat Purcell
Meeting Engagement

Liz Kane
Impactful Strategy

David Linetsky
Point-of-Care Marketing

Daniel Sontupe
Market Access

Amy Giles
Increasing Engagement

Matt Turner
Patient Affordability

Frank Burrell
Scientific Storytelling

Suma Ramadas, PhD
Medical Affairs

Stacey Gandler
Brand Nourishment

Matthew Durham
Omnidynamic Marketing

Brenda Snow
Authentic Patient Voice

Paul Theisen
Patient Acquisition

Bud Bilanich
Success Coach

Joey Cohen
Medication Adherence